Dihydropyrimidine Dehydrogenase in Livers from Mouse and Rat, and in Human Liver, Colon Tumors, and Mucosa in Relation to Anabolism of 5-Fluorouracil
- 1 January 1998
- book chapter
- Published by Springer Nature
- Vol. 431, 633-636
- https://doi.org/10.1007/978-1-4615-5381-6_122
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Leading Article: Oncologic, Endocrine & Metabolic: New antimetabolites in preclinical and clinical developmentExpert Opinion on Investigational Drugs, 1996
- Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenaseEuropean Journal Of Cancer, 1994
- 5-Ethynyluracil (776C85), a modulator of the therapeutic activity of 5-fluorouracilDrugs of the Future, 1994
- A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosaCancer, 1991
- Measurement of in vitro cellular pharmacokinetics of 5-fluorouracil in human and rat cancer cell lines and rat hepatocytes using a flow-through systemCancer Chemotherapy and Pharmacology, 1991
- Circadian rhythm of rat liver dihydropyrimidine dehydrogenaseBiochemical Pharmacology, 1988
- Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity.Journal of Clinical Investigation, 1988
- Chapter 3. Anti-Growth EffectsPublished by Elsevier ,1986